IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).

Kathleen N. Moore,Lainie P. Martin,Ursula A. Matulonis,Jason A. Konner,Shelly Seward,Todd Michael Bauer,David M. O'Malley,Raymond P. Perez,Woondong Jeong,Yinghui Zhou,Maurice Kirby,Satishkumar Mohanavelu,Rodrigo Ruiz-Soto,Michael J. Birrer

IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).

2016

Kathleen N. Moore
Lainie P. Martin
Ursula A. Matulonis
Jason A. Konner
Shelly Seward
Todd Michael Bauer
David M. O'Malley
Raymond P. Perez
Woondong Jeong
Yinghui Zhou
Maurice Kirby
Satishkumar Mohanavelu
Rodrigo Ruiz-Soto
Michael J. Birrer

5567Background: IMGN853 (mirvetuximab soravtansine) is an ADC, comprising a FRα-binding antibody linked to the tubulin-disrupting maytansinoid, DM4. Here we report on the IMGN853 monotherapy expans...

Keywords:

Folate Receptor Alpha
Ovarian cancer
Pathology
Cancer research
Platinum
MIRVETUXIMAB SORAVTANSINE
Antibody-drug conjugate
Medicine
Antibody
Maytansinoid
platinum resistant
single agent
epithelial ovarian cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations